NCT03435614View on ClinicalTrials.gov

Signs and Symptoms of Opioid-associated Iatrogenic Withdrawal in Critically Ill Adults

CompletedOBSERVATIONAL
Enrollment

29

Participants

Timeline

Start Date

February 26, 2018

Primary Completion Date

September 30, 2018

Study Completion Date

September 30, 2018

Conditions
Substance Withdrawal Syndrome
Interventions
DRUG

Opioids

Once an opioid dose reduction of 10% or greater is achieved, a daily assessment will be conducted by a physician using the DSM-5 criteria for opioid withdrawal. In addition, signs and symptoms of withdrawal will be collected daily by a blinded investigator.

Trial Locations (1)

H4A3J1

McGill University Health Centre, Montreal

All Listed Sponsors
lead

Marc M. Perreault

OTHER

NCT03435614 - Signs and Symptoms of Opioid-associated Iatrogenic Withdrawal in Critically Ill Adults | Biotech Hunter | Biotech Hunter